Critical Contrast: Kamada (KMDA) versus Its Peers

Kamada (NASDAQ:KMDA – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Kamada to similar companies based on the strength of its institutional ownership, analyst recommendations, valuation, dividends, risk, profitability and earnings.

Profitability

This table compares Kamada and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Kamada 12.67% 9.36% 6.53%
Kamada Competitors -12,224.75% -204.85% -31.52%

Volatility & Risk

Kamada has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Kamada’s competitors have a beta of -1.84, indicating that their average stock price is 284% less volatile than the S&P 500.

Institutional & Insider Ownership

20.4% of Kamada shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 36.1% of Kamada shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Kamada and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Kamada $180.46 million $20.20 million 18.98
Kamada Competitors $688.58 million $7.69 million -18.30

Kamada’s competitors have higher revenue, but lower earnings than Kamada. Kamada is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Kamada and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kamada 0 0 4 0 3.00
Kamada Competitors 9940 15326 45736 1606 2.54

Kamada presently has a consensus target price of $13.75, suggesting a potential upside of 68.50%. As a group, “Biotechnology” companies have a potential upside of 133.50%. Given Kamada’s competitors higher probable upside, analysts plainly believe Kamada has less favorable growth aspects than its competitors.

Dividends

Kamada pays an annual dividend of $0.13 per share and has a dividend yield of 1.6%. Kamada pays out 30.2% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 1.3% and pay out 38.6% of their earnings in the form of a dividend. Kamada is clearly a better dividend stock than its competitors, given its higher yield and lower payout ratio.

Summary

Kamada beats its competitors on 11 of the 15 factors compared.

Kamada Company Profile

(Get Free Report)

Kamada Ltd. is an Israeli biopharmaceutical company that develops, manufactures and markets plasma-derived therapies and specialty pharmaceutical products. Founded in 1990, the company is headquartered in Rehovot, Israel. Its products include Glassia, an alpha-1 proteinase inhibitor used to treat people with alpha-1 antitrypsin deficiency, and immune globulin therapies for conditions including rabies exposure, cytomegalovirus infection and varicella-zoster exposure. Kamada serves markets in the United States and internationally, selling products directly and through commercial partners.

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.